1. Summit Therapeutics Inc. (NASDAQ:SMMT)
Stock Upside: 129.89%
Market Capitalization: $10.82 billion
Summit Therapeutics Inc. (NASDAQ:SMMT) takes the top spot among the most promising healthcare stocks according to Wall Street analysts, and Summit Therapeutics Inc. (NASDAQ) does so with the highest stock upside on this list at 129.89%. Trading at $13.75, with Summit Therapeutics Inc. (NASDAQ) down 2.27%, the company has a market capitalization of $10.82 billion and 34 hedge fund holders. For investors searching for biotech stocks with the highest upside, oncology stocks, lung cancer stocks, bispecific antibody stocks, and healthcare stocks to buy now, Summit Therapeutics Inc. (NASDAQ) has become one of the most closely watched names because of ivonescimab, its lead cancer drug.
Summit Therapeutics Inc. (NASDAQ) made headlines on June 10 after withdrawing a $500 million proposed underwritten public offering that Summit Therapeutics Inc. (NASDAQ) had announced just one day earlier. Summit Therapeutics Inc. (NASDAQ) cited unfavorable market conditions for the withdrawal. For investors, the move was notable because stock offerings can pressure share prices by increasing the number of shares in the market, but withdrawing an offering can also raise questions about financing plans, timing, and investor appetite. In the case of Summit Therapeutics Inc. (NASDAQ), the offering was supposed to help fund ongoing research and development for ivonescimab.
Summit Therapeutics Inc. (NASDAQ)’s lead drug ivonescimab is a bispecific antibody designed to target two proteins that cancer cells rely on to grow and hide from the immune system. Summit Therapeutics Inc. (NASDAQ) is developing ivonescimab as its most important pipeline asset, and the drug is already approved in China. For Summit Therapeutics Inc. (NASDAQ), the appeal of ivonescimab comes from the fact that it targets both PD-1 and VEGF pathways, giving it a dual mechanism in cancer treatment. In oncology investing, bispecific antibodies can attract major attention because they are designed to hit disease from more than one angle.
Summit Therapeutics Inc. (NASDAQ) proposed the offering just nine days after its Chinese partner Akeso presented Phase 3 data from a China-based lung cancer trial of ivonescimab. Summit Therapeutics Inc. (NASDAQ) saw that data become a major talking point because the trial showed a 34% reduction in the risk of death compared with a competing therapy. For Summit Therapeutics Inc. (NASDAQ), those results sound highly encouraging on the surface, especially in non-small cell lung cancer, where survival data can shape how investors value a drug candidate.
Summit Therapeutics Inc. (NASDAQ) also faced some skepticism after a CNBC report raised concerns about whether the China-only trial data would translate cleanly to patients outside China. Dr. Suresh Ramalingam, executive director of the Winship Cancer Institute of Emory University, said he was mindful that the trial was conducted exclusively in China and that future investigations would be needed to understand how the results apply to patient populations outside China. For Summit Therapeutics Inc. (NASDAQ), that is a key debate because strong China-based data can support excitement, but US and global investors often want to see whether similar results can be confirmed in broader patient populations.
Summit Therapeutics Inc. (NASDAQ) remains one of the most promising healthcare stocks according to Wall Street analysts because the concern is not necessarily that ivonescimab does not work. Dr. Ramalingam described the results as good news for Chinese patients, but the issue for Summit Therapeutics Inc. (NASDAQ) is whether investors can assume those results will translate to US or global patients, especially when biological and population differences may affect treatment response. That makes Summit Therapeutics Inc. (NASDAQ) a high-upside but closely scrutinized biotech story.
Summit Therapeutics Inc. (NASDAQ) is a clinical-stage biopharmaceutical company, and Summit Therapeutics Inc. (NASDAQ)’s lead candidate ivonescimab is being evaluated in multiple Phase 3 trials for non-small cell lung cancer and other solid tumors. With a market capitalization of $10.82 billion, 34 hedge fund holders, and a stock upside of 129.89%, Summit Therapeutics Inc. (NASDAQ) leads this ranking because Wall Street analysts see the largest upside potential among the names listed. For investors looking for oncology stocks with major upside, bispecific antibody stocks, lung cancer biotech stocks, and promising healthcare stocks according to analysts, Summit Therapeutics Inc. (NASDAQ) has the clearest high-risk, high-reward profile in this group.
READ ALSO: Top 5 Best Biotech Stocks To Watch Now and Top 5 Biotech Stocks to Buy With Up to 215% Projected EPS Growth.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
